Epigenomics AG Announces H1 2013 and Q2 2013 Financial Results and Reports on Operational Highlights
07.08.2013
Berlin, Germany, and U.S.A. - Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the first half and second quarter of 2013 ending June 30.
Revenue in Q2 2013 increased by 120% to EUR 343 thousand compared to Q2 2012 Operating costs decreased by 44% to EUR 2,098 thousand over Q2 2012 EBIT in Q2 improved by 53% to EUR -1,607 thousand compared to Q2 2012 Net cash flow in H1 2013 positive due to successful capital increase in January Level 1 ADR program established